MODELING THE PARKINSONIAN TREMOR AND ITS TREATMENT Supervisor : Dr Towhidkhah Designed by Yashar Sarbaz Amirkabir University of Technology.

Slides:



Advertisements
Similar presentations
1 Chapter 49 Neurotransmitters and Disorders of the Basal Ganglia Copyright © 2012, American Society for Neurochemistry. Published by Elsevier Inc. All.
Advertisements

Cortically OriginatedMovement Cortically Originated Movement I. Motor Tract (corticospinal tractus) Extrapyramidal System (basal ganglia) Cerebellum Praxis.
Parkinson's Disease Animal Models and Possible Treatments.
BASAL NUCLEI (Basal Ganglia).
Basal Ganglia and Motor Control L21
Basal Ganglia Masses of gray matter found deep within the cortical white matter Masses of gray matter found deep within the cortical white matter Composed.
Basal Ganglia, Cerebellum and Movement
Movement part 2. Cerebellum and Brainstem KW p. 363.
Brain Control of Movement. Motor Control Hierarchy  High level – plans and executes strategy Association areas of cortex Basal ganglia gives the “go”
DBS on Parkinson’s Disease By: Christopher Ross DeSanto BME 181 / February 11, 2010.
Neural Control of Muscle. Quick Review: Spinal Cord Flexors Extensors.
Medical Robotics Application for Motion Emulation of Parkinsonian ECE 7995 Advisor Dr. Abhilash Pandya Group #2 Ranvir Hara Ravanpreet Kaur Gaganjeet Hans.
Investigations in Deep Brain Stimulation: Neurostimulating Electrodes March 9, 2001 Tom Chiesl, Eric Faulring, Elizabeth Nunamaker, Jonathan Yuen.
Dementia. Definition Loss of function in multiple cognitive abilities Assuming the individual had normal abilities before the onset Many of the 70 recognized.
Parkinson’s Test Device Development Erin Sikkel and Tiffany Feltman.
Parkinson’s Test Device Development Erin Sikkel and Tiffany Feltman.
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
Is it a neurodegenerative brain disorder that progresses slowly in most people.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Parkinson’s Disease By Devin Cornford
Some Terminologies White matter : myelinated fibre tracts White matter : myelinated fibre tracts Gray matter : areas of neuronal cell bodies Gray matter.
Pooya Pakarian Presentation based on:
Basal Ganglia. Involved in the control of movement Dysfunction associated with Parkinson’s and Huntington’s disease Site of surgical procedures -- Deep.
Supervisor: Dr Towhidkhah Designed by Yashar Sarbaz
Subthalamic GAD Gene Therapy in a Parkinson’s Disease Rat Model
Aaron Mulheren, Kathryn Wilson, MSN, APN, Milind Deogaonkar, MD
Making Things Happen - 2 Motor Disorders How Your Brain Works - Week 7 Dr. Jan Schnupp HowYourBrainWorks.net.
Parkinson’s Disease storyboard. Possible Intro Scenario As an resident at Normal Hospital, you are beginning your rotation in neurology. Your supervisor,
The Basal Ganglia. I.Functional anatomy A. Input and output components cerebral cortex  BG  thalamus (VA)  frontal lobe. B. Parallel circuits C. Neurotransmitters.
Neuroscience 1 Pause for thought: Probably 100 million neurones fire during skilled movements.
BY: MACKENZIE SOARES ALYSSA MEDIEROS STEPHANIE GARDNER Parkinson's Disease.
PARKINSON’S DISEASE By Courtney and Niral. WHAT IS IT?  Parkinson's disease (PD) is chronic and progressive movement disorder, meaning that symptoms.
Neurotransmitters, Parkinson’s disease and depression
PhD MD MBBS Faculty of Medicine Al Maarefa Colleges of Science & Technology Faculty of Medicine Al Maarefa Colleges of Science & Technology Lecture – 9:
MOTOR AREAS EXTRAPYRAMIDAL SYSTEM
BASAL GANGLIA Basal ganglia are subcorticle nuclei of grey matter located in the interior part of cerebrum near about base 3.
Quantitative Detection of Parkinson's Disease Symptoms Advisor: Dr. Chris Kao Project Team: Kylen Bares Eddie Cao.
Quantitative Detection of Parkinson's Disease Symptoms Advisor: Dr. Anita Mahadevan-Jansen Faraz Ali James Lugge Ernest Moore Mahesh Parlikad.
Quantitative Detection of Parkinson's Disease Symptoms Advisor: Dr. Chris Kao Project Team: Kylen Bares Eddie Cao.
Basal Ganglia Principles of neural sciences 5 th ed. The human brain: an introduction to its functional anatomy 6 th ed. 林 永 煬 國立陽明大學 腦科學研究所.
Quantitative Detection of Parkinson's Disease Symptoms Advisor: Dr. Anita Mahadevan-Jansen Faraz Ali James Lugge Ernest Moore Mahesh Parlikad.
Figure 18.1 Motor components of the human basal ganglia.
Separating Storage from Retrieval Dysfunction of Temporal Memory in Parkinson’s Disease Malapani, Deweer & Gibbon (2002) Tiffany Wang.
Dopamine by Leila Burridge and Emily Little. Dopamine and It’s Uses ●Neurotransmitter ●Helps transmit signals in brain and other vital areas ●Found in.
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
Extrapyramidal pathway
PARKINSON’S DISEASE Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine.
Parkinson’s Test Device Development Tiffany Feltman Erin Sikkel.
STRUCTURE AND CIRCUITS OF THE BASAL GANGLIA Rastislav Druga Inst. of Anatomy, 2nd Medical Faculty.
Brain Mechanisms of Movement Lecture 19. Hierarchical Control of Movement n Association cortices & Basal Ganglia l strategy : goals & planning l based.
Neurotransmitters in the Brain. What are the different neurotransmitters in the brain? Currently, over 60 different molecules meet the criteria for being.
How is Parkinson’s disease Diagnosed? And What Are the Treatment options?
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
Quantitative Detection of Parkinson's Disease Symptoms Advisor: Dr. Anita Mahadevan-Jansen Faraz Ali James Lugge Ernest Moore Mahesh Parlikad.
Parkinson’s Disease.
THE NERVE IMPULSE.
Nitric Oxide (NO) and How it Regulates Motor Function
Prediction of Parkinson’s Disease Tremor Onset Using Artificial Neural Networks Kevin Warwick.
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
Quantitative Detection of Parkinson's Disease Symptoms
Motor Fluctuations in Parkinson Disease: Options and Strategies
Quantitative Detection of Parkinson's Disease Symptoms
Basal ganglia function
Basal Ganglia Lec 13.
MODELING THE PARKINSONIAN TREMOR AND ITS TREATMENT
From Anatomy to Electrophysiology: Clinical Lasker Goes Deep
BASAL NUCLEI. BASAL NUCLEI Basal Ganglia Functions Compare proprioceptive information and movement commands. Sequence movements. Regulate muscle tone.
Presentation transcript:

MODELING THE PARKINSONIAN TREMOR AND ITS TREATMENT Supervisor : Dr Towhidkhah Designed by Yashar Sarbaz Amirkabir University of Technology

TITLES 1. INTRODUCTION OF PARKINSON’S DISEASE (PD) 2. SIMPLE MODELING 3. COMPLETING THE MODEL 4. MODELING THE TREATMENTS

1.Intoduction of PD 1-1. Origin of PD (Basal ganglia) 1-2. Parts of Basal ganglia (BG) 1-3. PD & it’s symptoms

1-1.Origion of PD (BG)

1-2.Parts of BG

1-3.PD & it’s symptoms Reason of PD: Loss of nerve cells in substantia nigra pars compacta Low level of Dopamine in patient’s brain Changing activity of other blocks

1-3.PD and it’s symptoms Symptoms of PD: Hypokinesia Akinesia: lack of slowness of spontaneous and associative movement Rigidity: increased tone on passive manipulation of joints Tremor:rhythmic,involuntary,oscillatory movement around 4-6 Hz

Clinical Data Recording Velocity laser recording of rest tremor

2.Simple modeling 2-1.Information about connections of Basal ganglia 2-2.Information about each block of Basal ganglia 2-3.Presenting mathematical model

2-1.Connection of BG The number of input and output of each block The type of each input to block (Inhibitory and excitatory effect ) The strength changes of connections in patient and healthy cases A gain corresponding to Dopamine changes

2-2.Each block of BG There are not detailed information about function of each block The major criteria for separating the different parts of BG are their anatomical and structural appearance and the kind of neurotransmitters Each block contain large value of neurons

Behavior of single neuron Membrane resistance Membrane capacitance longitudinal resistance

2-3.Mathematical model

Changing activity of blocks HealthyPatient

Changes of strengths of connections

Block diagram of model

Relations of each blocks

Model response for illness case ( g=10 )

Model response for treated case ( g=1 )

Sample of clinical Data

Comparing power spectra of clinical Data and model response Clinical DataModel Response

3.Completing the model 3-1.Synaptic transmission 3-2.Noise sources in synaptic transmission of healthy persons 3-3.Noise sources in synaptic transmission of patients 3-4.Completing the model

3-1.Synaptic transmission Step1 Step2

3-1.Synaptic transmission Step3&4

3-1.Synaptic transmission step5

3-1.Synaptic transmission step6

3-2.Noise sources in synaptic transmission of healthy persons Calsium amount in cell Voltage gated channels Diffusion of neurotransmitters Ligand gated channels

3-3.Noise sources in synaptic transmission of patients Lower of uptake Up regulation Diffusion of neurotransmitters

3-4.Completing the model Replacing with Considering normal physiological Tremor:

Comparing results with clinical data g2rof record Model response with a=0.2

Comparing results with clinical data S15rof record Model response with a=0.2&b=0.2

Changing activity of blocks

4.MODELING THE TREATMENTS 4-1.Kinds of PD treatments 4-2.Modeling drug effect 4-3.Modeling DBS effect 4-4.Prediction based on the model

4-1.Kinds of Treatments 1-1. Medical treatment 1-2. Deep Brain Stimulation

Medical Treatment Levodopa Drug L-depernil Drug

DBS Target of Stimulation GPi: The Globus Pallidus Internal STN:The Subthalamic Nucleus Vim: The Ventro-Intermediate nucleus Thlamus

4-2.Modeling drug effect Pharmacodynamics Pharmacokinetics

Pharmacodynamics Input is Levodopa drug Output is plasma level of drug

Model and clinical data

Relation of Pharmacodynamics

Pharmacokinetics input is plasma level of drug Output is g parameter of main model

Pharmacokinetics parts A nonlinear system (Saturation element) A first order system Scaling part

Response signal of Parmacodynamics part

Response signal of Pharmacokinetics part

Simple model response to drug prescription

Complete model response to drug prescription

4-3.Modeling DBS effect Characteristics of the common DBS signal: 1. Frequency greater than Pulse width about Amplitude of stimulation voltage nearly 3 v

DBS characteristic for different subjects

Clinical data of subjects when DBS switch to on

Clinical data of subjects when DBS switch to off

Relation of DBS

,

Variation of Parameter of g in DBS sec

Response of the simple model sec

Response of the complete model sec

4-4.Prediction based on the model Offering a new medical treatment Optimization of the levodopa usage

Problems of Levodopa usage

4-4-1.Offering a new medical treatment

Including GABA effect

Model response with different g & k=1 g=10 g=1

Model response with g=10 & k=0.1

Model response with g=5 & k=0.1

4-4-2.Optimization of the levodopa usage

Optimization problem

Answer of optimization